Cinemark Holdings heads into its May 8 Q1 earnings print with short sellers backing off — but a stock that has already priced in some disappointment.
The most notable shift in positioning is the retreat in short interest. At 9.3% of the free float, the short base remains meaningful, but it has fallen roughly 8% over the past two weeks from a mid-April peak above 11.7 million shares. The borrow market reflects this lighter pressure: the cost to borrow has edged up 25% over the past week to 0.47%, yet remains well below levels that would signal a crowded trade. Availability is ample, with the lending pool far from stressed despite the stock's recent slide. The ORTEX short score of 51 — mid-range and declining from a recent high of 55 — reinforces the picture of a short-side position that is being trimmed rather than built. Options sentiment tells a similar story: the put/call ratio at 0.25 is only modestly above its 20-day average of 0.23, offering no sign of elevated hedging demand heading into the print.
That cautious-but-not-panicked posture stands against a stock that has already taken a beating. CNK is down 7.4% on the week and 6.8% over the past month, closing Monday at $27.26. The most recent earnings event — a print in early May 2026 — triggered a one-day drop of 7.7%. Before that, February's Q4 report produced a modest 1.7% decline followed by a 7.1% five-day recovery. The pattern suggests the stock can rebound sharply if the print surprises to the upside, but initial reactions have been punishing.
Analysts are broadly constructive, and recent activity has sharpened that view. JP Morgan's David Karnovsky lifted his target to $36 on Monday — the second raise in a month — while maintaining an Overweight. Wells Fargo moved to $36 in April. Morgan Stanley, the holdout, nudged its Equal-Weight target up to $30 from $28 at the end of April. The consensus mean target of $33.82 implies roughly 24% upside from current levels. Bulls point to a strong 2026 film slate, ongoing investments in premium formats, and a conservative leverage profile that leaves room for capital returns. The dividend score ranks in the 95th percentile of the universe, a nod to the company's recovery in capital distribution. Bears acknowledge the structural risks: attendance still running below pre-pandemic norms, with global declines only partially offset by higher ticket prices and concession spend.
The ownership picture adds a layer of interest. Orbis Investment Management — a known contrarian value shop — holds a 12.9% stake and added aggressively, taking on 3.6 million shares in the second half of 2025. Wellington and Millennium both added in the same period. Together, these positions suggest real money has been building a thesis on the box office recovery. On the insider side, CEO Sean Gamble sold 109,455 shares at $30.02 on April 6, worth approximately $3.3 million — a notable transaction that came as the stock was trading well above current levels.
Friday's report is less a test of whether the box office is recovering and more a question of whether attendance trends in Q1 — a historically softer quarter — were sufficient to sustain the margin structure that underpins the bullish EBITDA multiples the Street is paying.
See the live data behind this article on ORTEX.
Open CNK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
